Annual Dialysis Data Report 2016, JSDT Renal Data Registry

Ikuto Masakane, Masatomo Taniguchi, Shigeru Nakai, Kenji Tsuchida, Atsushi Wada, Satoshi Ogata, Takeshi Hasegawa, Takayuki Hamano, Norio Hanafusa, Junichi Hoshino, Shunsuke Goto, Keiichi Yamamoto, Jun Minakuchi, Hidetomo Nakamoto

研究成果: Article査読

42 被引用数 (Scopus)


The annual survey of The Japanese Society for Dialysis Therapy Renal Data Registry (JRDR) was conducted for 4396 dialysis facilities at the end of 2016, among which 4336 facilities (98.6%) responded. The response rate of the 2016 survey was comparable with the past, even though it was the second year after the new anonymization method. The number of chronic dialysis patients in Japan continues to increase every year; it has reached 329,609 at the end of 2016. The mean age was 68.15 years. The prevalence rate was 2597 patients per million population. Diabetic nephropathy was the most common primary disease among the prevalent dialysis patients (38.8%), followed by chronic glomerulonephritis (28.8%) and nephrosclerosis (9.9%). The rate of diabetic nephropathy and nephrosclerosis has been increasing year by year, whereas that of chronic glomerulonephritis was declining. The number of incident dialysis patients during 2016 was 39,344; it has remained stable since 2008. The average age was 69.40 years, and diabetic nephropathy (43.2%) was the most common cause in the incident dialysis patients. These patients caused by diabetes did not change in number for recent several years. Thirty-one thousand six hundred eight patients died in 2016; the crude mortality rate was 9.7%. The patients treated by hemodiafiltration (HDF) have been increasing rapidly from the revision of medical reimbursement for HDF therapy in 2012. It has attained 76,836 patients at the end of 2016, which were 21,503 greater than that in 2015. The number of peritoneal dialysis (PD) patients was 9021 in 2016, which had been slightly decreasing since 2014; 20.3% of PD patients treated in the combination of hemodialysis (HD) or HDF therapy. Six hundred thirty-five patients were treated by home HD therapy at the end of 2016; it increased by 63 from 2015. Trial registration: JRDR was approved by the ethical committee of JSDT and has been registered in "University hospital Medical Information Network (UMIN) Clinical Trials Registry" as an approved number of UMIN000018641 on August 8, 2015.

ジャーナルRenal Replacement Therapy
出版ステータスPublished - 08-11-2018

All Science Journal Classification (ASJC) codes

  • 腎臓病学
  • 泌尿器学
  • 移植


「Annual Dialysis Data Report 2016, JSDT Renal Data Registry」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。